PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.68%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-2.68%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-2.79%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
1.20%
Positive EPS growth while TRVN is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
2.99%
Positive diluted EPS growth while TRVN is negative. John Neff might view this as a strong relative advantage in controlling dilution.
3.80%
Share count expansion well above TRVN's 6.30%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
6.10%
Diluted share count expanding well above TRVN's 6.30%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
35.18%
Positive OCF growth while TRVN is negative. John Neff would see this as a clear operational advantage vs. the competitor.
35.60%
Positive FCF growth while TRVN is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13691.29%
Negative 10Y OCF/share CAGR while TRVN stands at 71.36%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
29.84%
Below 50% of TRVN's 89.49%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
58.26%
3Y OCF/share CAGR at 75-90% of TRVN's 70.34%. Bill Ackman would press for improvements in margin or overhead to catch up.
-7976.92%
Negative 10Y net income/share CAGR while TRVN is at 57.18%. Joel Greenblatt sees a major red flag in long-term profit erosion.
76.35%
5Y net income/share CAGR similar to TRVN's 77.52%. Walter Schloss might see both on parallel mid-term trajectories.
62.71%
3Y net income/share CAGR similar to TRVN's 68.19%. Walter Schloss would attribute it to shared growth factors or demand patterns.
1259.19%
Below 50% of TRVN's 17815.98%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
224.33%
Positive 5Y equity/share CAGR while TRVN is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
-84.52%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.18%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-26.68%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
20.47%
We increase R&D while TRVN cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-32.93%
We cut SG&A while TRVN invests at 4.22%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.